Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs).

被引：0
|
作者：
Sibon, David [1 ]
Cannas, Giovanna [2 ]
Barraco, Fiorenza [2 ]
Prebet, Thomas [3 ]
Vey, Norbert [4 ]
Banos, Anne [5 ]
Besson, Caroline [6 ]
Corm, Selim [7 ]
Blanc, Michel [7 ]
Slama, Borhane [8 ]
Perrier, Herve [2 ]
Fenaux, Pierre [9 ]
Wattel, Eric [2 ]
机构：
[1] GFM, Paris, France
[2] GFM, Lyon, France
[3] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[4] Hop Paoli Calmettes, Marseille, France
[5] GFM, Bayonne, France
[6] Univ Paris 11, CHU Bicetre, INSERM, U1012, Le Kremlin Bicetre, France
[7] GFM, Chambery, France
[8] GFM, Avignon, France
[9] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1632 / 1632
页数：1
相关论文
共 50 条
  • [1] Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents
    Sibon, David
    Cannas, Giovanna
    Baracco, Fiorenza
    Prebet, Thomas
    Vey, Norbert
    Banos, Anne
    Besson, Caroline
    Corm, Selim
    Blanc, Michel
    Slama, Bohrane
    Perrier, Herve
    Fenaux, Pierre
    Wattel, Eric
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (05) : 619 - 625
  • [2] Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs)
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Zhong, Jianhua
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    Hoenekopp, Albert
    MacBeth, Kyle J.
    BLOOD, 2016, 128 (22)
  • [3] Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
    Park, Sophie
    Hamel, Jean-Francois
    Toma, Andrea
    Kelaidi, Charikleia
    Thepot, Sylvain
    Campelo, Maria Diez
    Santini, Valeria
    Sekeres, Mikkael A.
    Balleari, Enrico
    Kaivers, Jennifer
    Sapena, Rosa
    Goetze, Katharina
    Mueller-Thomas, Catharina
    Beyne-Rauzy, Odile
    Stamatoullas, Aspasia
    Kotsianidis, Ioannis
    Komrokji, Rami
    Steensma, David P.
    Fensterl, Jaime
    Roboz, Gail J.
    Bernal, Teresa
    Ramos, Fernando
    Calabuig, Marisa
    Guerci-Bresler, Agnes
    Bordessoule, Dominique
    Cony-Makhoul, Pascale
    Cheze, Stephane
    Wattel, Eric
    Rose, Christian
    Vey, Norbert
    Gioia, Daniela
    Ferrero, Dario
    Gaidano, Gianluca
    Cametti, Giovanni
    Pane, Fabrizio
    Sanna, Alessandro
    Germing, Ulrich
    Sanz, Guillermo F.
    Dreyfus, Francois
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1591 - +
  • [4] IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Platzbecker, U.
    Almeida, A.
    List, A. F.
    Zhong, J.
    Wu, C.
    Mavrommatis, K.
    Beach, C. L.
    MacBeth, K. J.
    LEUKEMIA RESEARCH, 2017, 55 : S14 - S14
  • [5] IMPACT OF GENE MUTATIONS ON RESPONSE TO LENALIDOMIDE AND OS IN LOWER-RISK NON-DEL(5Q) MDS PATIENTS INELIGIBLE/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Fenaux, P.
    Giagounidis, A.
    Platzbecker, U.
    Almeida, A.
    List, A. F.
    Zhong, J.
    Wu, C.
    Mavrommatis, K.
    Beach, C. L.
    MacBeth, K. J.
    HAEMATOLOGICA, 2017, 102 : 39 - 39
  • [6] Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
    Kelaidi, C.
    Park, S.
    Sapena, R.
    Beyne-Rauzy, O.
    Coiteux, V.
    Vey, N.
    Stamatoullas, A.
    Choufi, B.
    Delaunay, J.
    Gourin, M-P
    Cheze, S.
    Ravoet, C.
    Ferrant, A.
    Escoffre-Barbe, M.
    Aljassem, L.
    Raffoux, E.
    Itzykson, R.
    Ades, L.
    Dreyfus, F.
    Fenaux, P.
    LEUKEMIA, 2013, 27 (06) : 1283 - 1290
  • [7] Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
    C Kelaidi
    S Park
    R Sapena
    O Beyne-Rauzy
    V Coiteux
    N Vey
    A Stamatoullas
    B Choufi
    J Delaunay
    M-P Gourin
    S Cheze
    C Ravoet
    A Ferrant
    M Escoffre-Barbe
    L Aljassem
    E Raffoux
    R Itzykson
    L Adès
    F Dreyfus
    P Fenaux
    Leukemia, 2013, 27 : 1283 - 1290
  • [8] Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
    A Toma
    O Kosmider
    S Chevret
    J Delaunay
    A Stamatoullas
    C Rose
    O Beyne-Rauzy
    A Banos
    A Guerci-Bresler
    S Wickenhauser
    D Caillot
    K Laribi
    B De Renzis
    D Bordessoule
    C Gardin
    B Slama
    L Sanhes
    B Gruson
    P Cony-Makhoul
    B Chouffi
    C Salanoubat
    R Benramdane
    L Legros
    E Wattel
    G Tertian
    K Bouabdallah
    F Guilhot
    A L Taksin
    S Cheze
    K Maloum
    S Nimuboma
    C Soussain
    F Isnard
    E Gyan
    R Petit
    J Lejeune
    V Sardnal
    A Renneville
    C Preudhomme
    M Fontenay
    P Fenaux
    F Dreyfus
    Leukemia, 2016, 30 : 897 - 905
  • [9] Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
    Toma, A.
    Kosmider, O.
    Chevret, S.
    Delaunay, J.
    Stamatoullas, A.
    Rose, C.
    Beyne-Rauzy, O.
    Banos, A.
    Guerci-Bresler, A.
    Wickenhauser, S.
    Caillot, D.
    Laribi, K.
    De Renzis, B.
    Bordessoule, D.
    Gardin, C.
    Slama, B.
    Sanhes, L.
    Gruson, B.
    Cony-Makhoul, P.
    Chouffi, B.
    Salanoubat, C.
    Benramdane, R.
    Legros, L.
    Wattel, E.
    Tertian, G.
    Bouabdallah, K.
    Guilhot, F.
    Taksin, A. L.
    Cheze, S.
    Maloum, K.
    Nimuboma, S.
    Soussain, C.
    Isnard, F.
    Gyan, E.
    Petit, R.
    Lejeune, J.
    Sardnal, V.
    Renneville, A.
    Preudhomme, C.
    Fontenay, M.
    Fenaux, P.
    Dreyfus, F.
    LEUKEMIA, 2016, 30 (04) : 897 - 905
  • [10] OUTCOME OF LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITHOUT 5Q DELETION AFTER FAILURE OF ERYTHROPOIESIS STIMULATING AGENTS
    Park, S.
    Hamel, J. F.
    Toma, A.
    Kelaidi, C.
    Thepot, S.
    Campelo Diez, M.
    Santini, V.
    Sekeres, M.
    Balleari, E.
    Kaivers, J.
    Goetze, K.
    Beyne-Rauzy, O.
    Stamatoullas, A.
    Kotsianidis, I.
    Komrokji, R.
    Steensma, D.
    Germing, U.
    Sanz, G.
    Dreyfus, F.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2017, 55 : S33 - S33
12345